HC Wainwright restated their buy rating on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report released on Friday morning. HC Wainwright currently has a $12.00 price objective on the biotechnology company’s stock.
Several other research firms have also recently issued reports on PIRS. BidaskClub cut Pieris Pharmaceuticals from a strong-buy rating to a buy rating in a report on Saturday, February 17th. ValuEngine upgraded Pieris Pharmaceuticals from a sell rating to a hold rating in a report on Friday, February 2nd. Finally, William Blair started coverage on Pieris Pharmaceuticals in a report on Wednesday, January 17th. They set an outperform rating on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Pieris Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $10.00.
Pieris Pharmaceuticals (PIRS) traded down $0.13 during mid-day trading on Friday, hitting $7.27. The stock had a trading volume of 2,180,000 shares, compared to its average volume of 1,150,437. Pieris Pharmaceuticals has a 1-year low of $2.26 and a 1-year high of $9.75. The firm has a market capitalization of $371.52, a PE ratio of -9.82 and a beta of 1.50.
A number of institutional investors have recently modified their holdings of the stock. Vident Investment Advisory LLC acquired a new position in Pieris Pharmaceuticals in the fourth quarter valued at $1,590,000. Millennium Management LLC boosted its holdings in Pieris Pharmaceuticals by 57.9% in the fourth quarter. Millennium Management LLC now owns 699,771 shares of the biotechnology company’s stock valued at $5,283,000 after acquiring an additional 256,622 shares during the last quarter. TIAA CREF Investment Management LLC boosted its holdings in Pieris Pharmaceuticals by 25.1% in the fourth quarter. TIAA CREF Investment Management LLC now owns 272,287 shares of the biotechnology company’s stock valued at $2,056,000 after acquiring an additional 54,710 shares during the last quarter. Two Sigma Investments LP acquired a new position in Pieris Pharmaceuticals in the fourth quarter valued at $734,000. Finally, Two Sigma Advisers LP acquired a new position in Pieris Pharmaceuticals in the fourth quarter valued at $294,000. Hedge funds and other institutional investors own 47.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3253421/hc-wainwright-reiterates-buy-rating-for-pieris-pharmaceuticals-pirs.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.